Stereotactic Body Radiation Therapy for Primary, Recurrent, and Metastatic Tumors in the Head-and-Neck Region

Farzan Siddiqui, Mehul Patel, Mumtaz Khan, Scott McLean, Jadranka Dragovic, JianYue Jin, Benjamin Movsas, Samuel Ryu

Research output: Contribution to journalArticle

76 Citations (Scopus)

Abstract

Purpose: To determine the feasibility, safety, and efficacy of stereotactic body radiation therapy (SBRT), also known as radiosurgery, in patients with head-and-neck cancers. Methods and Materials: Patients with pathologically proven malignant lesions in the head-and-neck region were treated using single-dose SBRT (S-SBRT) or fractionated SBRT (F-SBRT). Radiation doses were either single-fraction 13-18 Gy for S-SBRT or 36-48 Gy in five to eight fractions for F-SBRT. Response evaluation was based on clinical examinations and computed tomography/magnetic resonance imaging scans. Pre- and post-SBRT tumor dimensions were measured in three axes, and tumor volumes were calculated. Response evaluation also was performed using World Health Organization criteria. Results: Fifty-five lesions were treated in 44 patients (25 men, 19 women). There were three groups of patients: those with primary (n = 10), recurrent (n = 21), and metastatic tumors (n = 13). The predominant histologic type was squamous cell carcinoma (n = 33). The majority of lesions were treated using F-SBRT (n = 37). Based on radiographic and clinical assessment, a 77% (complete + partial response) response rate was noted. Percentage of reduction in tumor volume was 52% ± 38% based on follow-up scans in 24 patients. Tumor control rates at 1 year were 83.3% and 60.6% in the primary and recurrent groups, respectively. Median overall survival was 28.7, 6.7, and 5.6 months for the primary, recurrent, and metastatic groups, respectively. Radiation Therapy Oncology Group Grade 1-2 mucositis was noted in all patients treated for oropharyngeal or laryngeal lesions. Conclusions: The SBRT in single or fractionated doses offers a viable treatment option for selected patients with primary, recurrent, and metastatic head-and-neck cancers with functional preservation.

Original languageEnglish (US)
Pages (from-to)1047-1053
Number of pages7
JournalInternational Journal of Radiation Oncology Biology Physics
Volume74
Issue number4
DOIs
StatePublished - Jul 15 2009

Fingerprint

radiation therapy
Neck
Radiotherapy
tumors
Head
lesions
Neoplasms
dosage
cancer
Head and Neck Neoplasms
Tumor Burden
Mucositis
Radiation Oncology
Radiosurgery
evaluation
health
magnetic resonance
Squamous Cell Carcinoma
grade
safety

Keywords

  • Fractionated stereotactic body radiation therapy (F-SBRT)
  • Head-and-neck cancers
  • Reirradiation
  • Single-fraction stereotactic body radiation therapy (S-SBRT)

ASJC Scopus subject areas

  • Radiation
  • Oncology
  • Radiology Nuclear Medicine and imaging
  • Cancer Research

Cite this

Stereotactic Body Radiation Therapy for Primary, Recurrent, and Metastatic Tumors in the Head-and-Neck Region. / Siddiqui, Farzan; Patel, Mehul; Khan, Mumtaz; McLean, Scott; Dragovic, Jadranka; Jin, JianYue; Movsas, Benjamin; Ryu, Samuel.

In: International Journal of Radiation Oncology Biology Physics, Vol. 74, No. 4, 15.07.2009, p. 1047-1053.

Research output: Contribution to journalArticle

Siddiqui, Farzan ; Patel, Mehul ; Khan, Mumtaz ; McLean, Scott ; Dragovic, Jadranka ; Jin, JianYue ; Movsas, Benjamin ; Ryu, Samuel. / Stereotactic Body Radiation Therapy for Primary, Recurrent, and Metastatic Tumors in the Head-and-Neck Region. In: International Journal of Radiation Oncology Biology Physics. 2009 ; Vol. 74, No. 4. pp. 1047-1053.
@article{a96534c8ca464ef482afb67321be8e23,
title = "Stereotactic Body Radiation Therapy for Primary, Recurrent, and Metastatic Tumors in the Head-and-Neck Region",
abstract = "Purpose: To determine the feasibility, safety, and efficacy of stereotactic body radiation therapy (SBRT), also known as radiosurgery, in patients with head-and-neck cancers. Methods and Materials: Patients with pathologically proven malignant lesions in the head-and-neck region were treated using single-dose SBRT (S-SBRT) or fractionated SBRT (F-SBRT). Radiation doses were either single-fraction 13-18 Gy for S-SBRT or 36-48 Gy in five to eight fractions for F-SBRT. Response evaluation was based on clinical examinations and computed tomography/magnetic resonance imaging scans. Pre- and post-SBRT tumor dimensions were measured in three axes, and tumor volumes were calculated. Response evaluation also was performed using World Health Organization criteria. Results: Fifty-five lesions were treated in 44 patients (25 men, 19 women). There were three groups of patients: those with primary (n = 10), recurrent (n = 21), and metastatic tumors (n = 13). The predominant histologic type was squamous cell carcinoma (n = 33). The majority of lesions were treated using F-SBRT (n = 37). Based on radiographic and clinical assessment, a 77{\%} (complete + partial response) response rate was noted. Percentage of reduction in tumor volume was 52{\%} ± 38{\%} based on follow-up scans in 24 patients. Tumor control rates at 1 year were 83.3{\%} and 60.6{\%} in the primary and recurrent groups, respectively. Median overall survival was 28.7, 6.7, and 5.6 months for the primary, recurrent, and metastatic groups, respectively. Radiation Therapy Oncology Group Grade 1-2 mucositis was noted in all patients treated for oropharyngeal or laryngeal lesions. Conclusions: The SBRT in single or fractionated doses offers a viable treatment option for selected patients with primary, recurrent, and metastatic head-and-neck cancers with functional preservation.",
keywords = "Fractionated stereotactic body radiation therapy (F-SBRT), Head-and-neck cancers, Reirradiation, Single-fraction stereotactic body radiation therapy (S-SBRT)",
author = "Farzan Siddiqui and Mehul Patel and Mumtaz Khan and Scott McLean and Jadranka Dragovic and JianYue Jin and Benjamin Movsas and Samuel Ryu",
year = "2009",
month = "7",
day = "15",
doi = "10.1016/j.ijrobp.2008.09.022",
language = "English (US)",
volume = "74",
pages = "1047--1053",
journal = "International Journal of Radiation Oncology Biology Physics",
issn = "0360-3016",
publisher = "Elsevier Inc.",
number = "4",

}

TY - JOUR

T1 - Stereotactic Body Radiation Therapy for Primary, Recurrent, and Metastatic Tumors in the Head-and-Neck Region

AU - Siddiqui, Farzan

AU - Patel, Mehul

AU - Khan, Mumtaz

AU - McLean, Scott

AU - Dragovic, Jadranka

AU - Jin, JianYue

AU - Movsas, Benjamin

AU - Ryu, Samuel

PY - 2009/7/15

Y1 - 2009/7/15

N2 - Purpose: To determine the feasibility, safety, and efficacy of stereotactic body radiation therapy (SBRT), also known as radiosurgery, in patients with head-and-neck cancers. Methods and Materials: Patients with pathologically proven malignant lesions in the head-and-neck region were treated using single-dose SBRT (S-SBRT) or fractionated SBRT (F-SBRT). Radiation doses were either single-fraction 13-18 Gy for S-SBRT or 36-48 Gy in five to eight fractions for F-SBRT. Response evaluation was based on clinical examinations and computed tomography/magnetic resonance imaging scans. Pre- and post-SBRT tumor dimensions were measured in three axes, and tumor volumes were calculated. Response evaluation also was performed using World Health Organization criteria. Results: Fifty-five lesions were treated in 44 patients (25 men, 19 women). There were three groups of patients: those with primary (n = 10), recurrent (n = 21), and metastatic tumors (n = 13). The predominant histologic type was squamous cell carcinoma (n = 33). The majority of lesions were treated using F-SBRT (n = 37). Based on radiographic and clinical assessment, a 77% (complete + partial response) response rate was noted. Percentage of reduction in tumor volume was 52% ± 38% based on follow-up scans in 24 patients. Tumor control rates at 1 year were 83.3% and 60.6% in the primary and recurrent groups, respectively. Median overall survival was 28.7, 6.7, and 5.6 months for the primary, recurrent, and metastatic groups, respectively. Radiation Therapy Oncology Group Grade 1-2 mucositis was noted in all patients treated for oropharyngeal or laryngeal lesions. Conclusions: The SBRT in single or fractionated doses offers a viable treatment option for selected patients with primary, recurrent, and metastatic head-and-neck cancers with functional preservation.

AB - Purpose: To determine the feasibility, safety, and efficacy of stereotactic body radiation therapy (SBRT), also known as radiosurgery, in patients with head-and-neck cancers. Methods and Materials: Patients with pathologically proven malignant lesions in the head-and-neck region were treated using single-dose SBRT (S-SBRT) or fractionated SBRT (F-SBRT). Radiation doses were either single-fraction 13-18 Gy for S-SBRT or 36-48 Gy in five to eight fractions for F-SBRT. Response evaluation was based on clinical examinations and computed tomography/magnetic resonance imaging scans. Pre- and post-SBRT tumor dimensions were measured in three axes, and tumor volumes were calculated. Response evaluation also was performed using World Health Organization criteria. Results: Fifty-five lesions were treated in 44 patients (25 men, 19 women). There were three groups of patients: those with primary (n = 10), recurrent (n = 21), and metastatic tumors (n = 13). The predominant histologic type was squamous cell carcinoma (n = 33). The majority of lesions were treated using F-SBRT (n = 37). Based on radiographic and clinical assessment, a 77% (complete + partial response) response rate was noted. Percentage of reduction in tumor volume was 52% ± 38% based on follow-up scans in 24 patients. Tumor control rates at 1 year were 83.3% and 60.6% in the primary and recurrent groups, respectively. Median overall survival was 28.7, 6.7, and 5.6 months for the primary, recurrent, and metastatic groups, respectively. Radiation Therapy Oncology Group Grade 1-2 mucositis was noted in all patients treated for oropharyngeal or laryngeal lesions. Conclusions: The SBRT in single or fractionated doses offers a viable treatment option for selected patients with primary, recurrent, and metastatic head-and-neck cancers with functional preservation.

KW - Fractionated stereotactic body radiation therapy (F-SBRT)

KW - Head-and-neck cancers

KW - Reirradiation

KW - Single-fraction stereotactic body radiation therapy (S-SBRT)

UR - http://www.scopus.com/inward/record.url?scp=67649519734&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=67649519734&partnerID=8YFLogxK

U2 - 10.1016/j.ijrobp.2008.09.022

DO - 10.1016/j.ijrobp.2008.09.022

M3 - Article

C2 - 19327895

AN - SCOPUS:67649519734

VL - 74

SP - 1047

EP - 1053

JO - International Journal of Radiation Oncology Biology Physics

JF - International Journal of Radiation Oncology Biology Physics

SN - 0360-3016

IS - 4

ER -